ADDRESS-LC:
Long Covid Study
Advancing Potential Treatments for Long COVID begins with you.
The trial drug Bezisterim (NE3107), is a new investigational drug that may help reduce certain kinds of inflammation present in Long COVID that cause impaired cognition and fatigue. Bezisterim may work by blocking production of substances that cause inflammation through toll-like receptors (TLR) pathways known to cause issues in Long COVID. Currently bezisterim is also in clinical development for Alzheimer’s and Parkinson’s diseases, two neurodegenerative diseases where inflammation causes neurologic symptoms and cognitive decline. This trial is testing whether bezisterim can improve cognitive function or brain fog and fatigue in individuals with Long COVID.
Contact a study site near you to find out if you’re eligible to join the study.
You may be eligible if you:
- Are 18 to 64 years of age at Screening
- Have been diagnosed with Long COVID, as defined below:
- Symptoms of at least fatigue and neurocognitive impairment attributed to an index SARS-CoV-2 infection that occurred at least 3 months prior to screening. Index SARS-CoV-2 infection defined as either an episode of COVID-19 with a positive nucleic acid or antigen test during acute illness, as documented in the medical record or a documented clinical diagnosis of COVID-19 from the participant’s physician to which the symptoms are most attributed.
- Symptoms cannot be explained by an alternative diagnosis, in the opinion of the investigator
- Have symptoms for at least 3 months and not longer than 24 months from the index SARS-CoV-2 infection
- Agree to maintain any other regular medications at current doses for the duration of the trial
Additional criteria apply
You may not be eligible if you:
- Were diagnosed with attention deficit hyperactivity disorder (ADHD) prior to index COVID-19 infection
- Are currently taking or have received naltrexone within 30-days prior to the screening visit.
Funding
The study is funded through the Defense Health Agency, Congressionally Directed Medical Research Programs’ Peer-Reviewed Medical Research Program under Award No. HT9425-24-1-0113. Opinions, interpretations, conclusions, and recommendations described in this website are those of the study sponsor and are not necessarily endorsed by the Department of Defense.
